Nature Communications (Apr 2022)
Modification of BRCA1-associated breast cancer risk by HMMR overexpression
- Francesca Mateo,
- Zhengcheng He,
- Lin Mei,
- Gorka Ruiz de Garibay,
- Carmen Herranz,
- Nadia García,
- Amanda Lorentzian,
- Alexandra Baiges,
- Eline Blommaert,
- Antonio Gómez,
- Oriol Mirallas,
- Anna Garrido-Utrilla,
- Luis Palomero,
- Roderic Espín,
- Ana I. Extremera,
- M. Teresa Soler-Monsó,
- Anna Petit,
- Rong Li,
- Joan Brunet,
- Ke Chen,
- Susanna Tan,
- Connie J. Eaves,
- Curtis McCloskey,
- Razq Hakem,
- Rama Khokha,
- Philipp F. Lange,
- Conxi Lázaro,
- Christopher A. Maxwell,
- Miquel Angel Pujana
Affiliations
- Francesca Mateo
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Zhengcheng He
- Department of Pediatrics, University of British Columbia
- Lin Mei
- Department of Pediatrics, University of British Columbia
- Gorka Ruiz de Garibay
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Carmen Herranz
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Nadia García
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Amanda Lorentzian
- Department of Pediatrics, University of British Columbia
- Alexandra Baiges
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Eline Blommaert
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Antonio Gómez
- Department of Biosciences, Faculty of Sciences and Technology (FCT), University of Vic – Central University of Catalonia (UVic-UCC), Vic
- Oriol Mirallas
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Anna Garrido-Utrilla
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Luis Palomero
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Roderic Espín
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Ana I. Extremera
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- M. Teresa Soler-Monsó
- Department of Pathology, University Hospital of Bellvitge, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Anna Petit
- Department of Pathology, University Hospital of Bellvitge, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Rong Li
- Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University
- Joan Brunet
- Hereditary Cancer Program, Catalan Institute of Oncology, Girona Biomedical Research Institute (IDIBGI)
- Ke Chen
- Department of Pediatrics, University of British Columbia
- Susanna Tan
- Terry Fox Laboratory, British Columbia Cancer Agency
- Connie J. Eaves
- Terry Fox Laboratory, British Columbia Cancer Agency
- Curtis McCloskey
- Princess Margaret Cancer Research Centre, University Health Network
- Razq Hakem
- Princess Margaret Cancer Research Centre, University Health Network
- Rama Khokha
- Princess Margaret Cancer Research Centre, University Health Network
- Philipp F. Lange
- Department of Pathology, University of British Columbia
- Conxi Lázaro
- Hereditary Cancer Program, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Christopher A. Maxwell
- Department of Pediatrics, University of British Columbia
- Miquel Angel Pujana
- ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- DOI
- https://doi.org/10.1038/s41467-022-29335-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
The effect of hyaluronan-mediated motility receptor (HMMR) expression in BRCA1-associated breast cancer risk remains unknown. Here, HMMR overexpression induces the activation of cGAS-STING and non-canonical NF-κB signalling, instigating an immune permissive environment for breast cancer development.
